» Articles » PMID: 9563897

Induction of Thymidine Phosphorylase Activity and Enhancement of Capecitabine Efficacy by Taxol/taxotere in Human Cancer Xenografts

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 1998 May 14
PMID 9563897
Citations 96
Authors
Affiliations
Soon will be listed here.
Abstract

Thymidine phosphorylase (dThdPase) is an essential enzyme for the activation of the cytostatics capecitabine (N(4)-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine) and its intermediate metabolite [5'-deoxy-5-fluorouridine (5'-dFUrd)] to 5-fluorouracil in tumors. We have tried to identify the best partners of capecitabine in combination therapy, such as dThdPase up-regulators, which may enhance the efficacy of this compound. Among various cytostatics studied with the WiDr human colon cancer xenograft model, Taxol, Taxotere, and mitomycin C greatly increased levels of human dThdPase in tumors, and cyclophosphamide slightly increased the enzyme level. These cytostatics simultaneously increased the levels of human tumor necrosis factor alpha (TNFalpha), which is an up-regulator of dThdPase. In cultures of the WiDr cells, however, Taxol did not up-regulate TNFalpha to a detectable level and only slightly enhanced levels of dThdPase. These results suggest that Taxol might indirectly elevate TNFalpha in tumor cells, which in turn up-regulated dThdPase in the tumor cells in the WiDr cancer xenograft. In the combination therapy, the efficacy of Taxol and Taxotere with either capecitabine or 5'-dFUrd was more than just additive. In contrast, Taxol and either 5-fluorouracil or UFT (a mixture of tegafur and uracil) in combination showed only additive activity. Taxol and Taxotere might enhance the efficacy of capecitabine and 5'-dFUrd, probably by modulating dThdPase activity in tumor tissues.

Citing Articles

Capecitabine-based chemotherapy in early-stage triple-negative breast cancer: a meta-analysis.

Bai J, Yao X, Pu Y, Wang X, Luo X Front Oncol. 2023; 13:1245650.

PMID: 37954087 PMC: 10634425. DOI: 10.3389/fonc.2023.1245650.


Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial.

Yang H, Xu L, Guan S, Hao X, Ge Z, Tong F BMC Cancer. 2022; 22(1):1357.

PMID: 36577958 PMC: 9795638. DOI: 10.1186/s12885-022-10439-0.


Efficacy and Safety of Capecitabine for Triple-Negative Breast Cancer: A Meta-Analysis.

Xun X, Cao Q, Hong P, Rai S, Zhou Y, Liu R Front Oncol. 2022; 12:899423.

PMID: 35875141 PMC: 9300946. DOI: 10.3389/fonc.2022.899423.


Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial.

Joensuu H, Kellokumpu-Lehtinen P, Huovinen R, Jukkola A, Tanner M, Ahlgren J J Clin Oncol. 2022; 40(10):1051-1058.

PMID: 35020465 PMC: 8966968. DOI: 10.1200/JCO.21.02054.


Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5'-deoxy-5-fluorocytidine (5'-DFCR).

Gao Y, Zens P, Su M, Gemperli C, Yang H, Deng H J Exp Clin Cancer Res. 2021; 40(1):138.

PMID: 33874986 PMC: 8056724. DOI: 10.1186/s13046-021-01938-2.